Limfoma klinikiniai tyrimai Ilinoisas
23 tyrimai dėl Limfoma ieško dalyvių vietose Ilinoisas.
Miestai Ilinoisas
Oficialus tyrimo tekstas (anglų kalba)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07015242CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Renkami dalyviai1/2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-11 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- University of Illinois Cancer Center, Chicago
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06624085Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT04588922Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- University of Chicago, Chicago
- Northwestern University, Evanston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07284433A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT04104776A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northwestern, Chicago
- University of Chicago, Chicago
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-03 · NCT06960993DALY II USA/ MB-CART2019.1 for DLBCL
- Robert H Lurie Cancer Center, Chicago
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0024), Chicago
Renkami dalyviai1/2 fazė
6 Months – 17 Years · Visoms lytims · Atnaujinta 2026-07-06 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT05131022Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Northwestern Memorial Hospital, Chicago
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-16 · NCT03328078The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Chicago, Zion
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-27 · NCT06915246A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-04 · NCT07294677Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- University of Chicago Comprehensive Cancer Center, Chicago
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-20 · NCT05745285Avo In R/R And Previously Untreated MCL
- University of Chicago Medical Center, Chicago
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-21 · NCT04855695Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- OSF Saint Anthony's Health Center, Alton
Renkami dalyviai3 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-13 · NCT05006482Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-22 · NCT04234048Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.